The Aporia
Reuters. (2026, September 30). U.S. says two Indian nationals indicted in counterfeit Ozempic smuggling scheme. The Hindu. https://www.thehindu.com/news/international/us-says-two-indian-nationals-indicted-in-counterfeit-ozempic-smuggling-scheme/article71526547.ece
Reuters. “U.S. says two Indian nationals indicted in counterfeit Ozempic smuggling scheme.” The Hindu, 30 Sept. 2026, https://www.thehindu.com/news/international/us-says-two-indian-nationals-indicted-in-counterfeit-ozempic-smuggling-scheme/article71526547.ece.
Reuters. “U.S. says two Indian nationals indicted in counterfeit Ozempic smuggling scheme.” The Hindu, September 30, 2026. https://www.thehindu.com/news/international/us-says-two-indian-nationals-indicted-in-counterfeit-ozempic-smuggling-scheme/article71526547.ece.
Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.
Two Indian nationals, Swapnadip Roy and Vicky Ramancha, have been indicted by a US federal grand jury for allegedly smuggling and selling counterfeit Ozempic between July 2023 and April 2024. Ozempic, a popular weight-loss drug costing hundreds of dollars per month, was obtained from China and sold to US distributors at discounted prices. Roy pleaded not guilty after being extradited from Italy, while Ramancha remains at large. The counterfeit medication included packaging meant to deceive buyers into believing they were purchasing genuine products. Despite the FDA seizing some counterfeit Ozempic in December 2023 and issuing a public warning, the scheme continued unabated.